Comparative Pharmacology
Head-to-head clinical analysis: ACTIVELLA versus ALORA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIVELLA versus ALORA.
ACTIVELLA vs ALORA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.
None Documented
None Documented
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
The terminal elimination half-life of estradiol is approximately 13-19 hours following transdermal administration, reflecting slow release from the skin depot and ongoing metabolism. This half-life allows for continuous hormone levels with once- or twice-weekly dosing.
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Alora (estradiol transdermal system) is eliminated primarily via hepatic metabolism, with approximately 60% of a dose excreted in urine as glucuronide and sulfate conjugates, and about 40% excreted in feces via biliary elimination.
Category C
Category C
Estrogen/Progestin Combination
Estrogen